Primidone (Mysoline): Dual Inhibitor of TRPM3 and RIPK1 in ALS Models

Executive Summary:
Primidone, also known as Mysoline, is a solid antiepileptic compound used clinically and in research for its dual inhibition of TRPM3 cation channels (IC₅₀: 0.6–1.2 μM) and RIPK1 kinase (50% inhibition at 0.1–1 μM, full at ≥10 μM) (source: product_spec). In SOD1^G93A mouse models of amyotrophic lateral sclerosis (ALS), daily oral primidone (25 mg/kg) delays symptom onset and improves motor performance (source: Wei et al., 2023). In ALS patients, 62.5 mg/day oral dosing reduces serum RIPK1 and IL-8, both validated as peripheral biomarkers correlating with ALS severity (source: Wei et al., 2023). Primidone is insoluble in water but dissolves in DMSO and ethanol with gentle warming and sonication (source: product_spec). APExBIO supplies research-grade Primidone (SKU: B2120) with detailed handling recommendations.

Biological Rationale

ALS is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration and elevated neuroinflammation. No cure exists and current therapies are limited (source: Wei et al., 2023). RIPK1 kinase is implicated in cell death pathways (apoptosis, necroptosis) and neuroinflammatory signaling, with increased activation observed in both ALS patient tissue and animal models. TRPM3 channels are involved in neuronal excitability and pain processing, with emerging links to neurodevelopmental and inflammatory pathomechanisms (source: site_article).

Mechanism of Action of Primidone

Primidone inhibits the TRPM3 cation channel with an IC₅₀ of 0.6–1.2 μM, blocking cation influx and modulating neuronal excitability (source: product_spec). It non-competitively inhibits RIPK1 kinase, achieving ~50% inhibition at 0.1–1 μM and full inhibition at ≥10 μM (source: Wei et al., 2023). This dual mechanism reduces necroinflammatory signaling and cell death. Primidone also inhibits human serum paraoxonase 1 (hPON1; IC₅₀ 0.87 mM, K_i 0.410±0.184 mM) but does not inhibit human aromatase (CYP19) (source: product_spec).

Evidence & Benchmarks

• RIPK1 activation is observed in spinal cord tissue from ALS patients and mouse models (source: Wei et al., 2023).
• Oral primidone (25 mg/kg/day) delays symptom onset and improves motor performance in SOD1^G93A ALS mice (source: Wei et al., 2023).
• Primidone (62.5 mg/day, orally) in ALS patients reduces serum RIPK1 and IL-8, correlating with symptom severity (source: Wei et al., 2023).
• Primidone shows no measurable inhibition of human aromatase (CYP19) at relevant concentrations (source: product_spec).
• TRPM3 inhibition by primidone is highly selective in human in vitro and animal models (source: site_article).
• For validated workflows, see also: Primidone (Mysoline) in ALS Models (this article adds clinical dosing and biomarker data).

Applications, Limits & Misconceptions

Primidone is applied as an antiepileptic, anti-essential tremor drug, and now as a tool compound for probing RIPK1- and TRPM3-mediated neuroinflammation. In ALS research, its dual inhibition translates to biomarker reduction and functional benefit in preclinical models. In adenomyosis models, intraperitoneal primidone (2 mg/kg/day) reduces myometrial infiltration and pain (source: product_spec). However, efficacy and safety outside validated concentrations or indications remain unproven.

Common Pitfalls or Misconceptions

• Primidone is not water-soluble; improper solvents may affect assay results (source: product_spec).
• Long-term solutions are not recommended for storage due to compound instability (source: product_spec).
• Doses higher than 62.5 mg/day in humans are not clinically validated for ALS biomarker reduction (source: Wei et al., 2023).
• No evidence supports Primidone's efficacy in conditions unrelated to TRPM3 or RIPK1 pathways (workflow_recommendation).
• It does not inhibit human aromatase and should not be used as an endocrine modulator (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• in vitro TRPM3 inhibition | 0.6–1.2 μM | human/rodent cell models | blocks cation influx, reduces excitability | product_spec
• in vitro RIPK1 inhibition | 0.1–1 μM (50%); ≥10 μM (full) | cell culture | suppresses necroptosis and inflammation | DOI
• ALS mouse model dosing | 25 mg/kg/day, oral | SOD1^G93A mice | delays symptom onset, improves motor scores | DOI
• ALS clinical dosing | 62.5 mg/day, oral | ALS patients | reduces serum RIPK1 and IL-8 | DOI
• adenomyosis model dosing | 2 mg/kg/day, intraperitoneal | mouse | reduces myometrial infiltration, analgesia | product_spec
• solution preparation | ≥10.91 mg/mL in DMSO, ≥3.1 mg/mL in ethanol | compound handling | for stock solutions, requires warming/sonication | product_spec
• storage | -20°C (solid) | compound storage | preserves stability | product_spec

For extended protocol design and disease model benchmarking, see Primidone (Mysoline): Protocols & Precision; this article expands on clinical translation and biomarker endpoints.

Conclusion & Outlook

Primidone (APExBIO SKU: B2120) is a validated dual inhibitor of TRPM3 and RIPK1, with translational utility in ALS and other neuroinflammatory models. Its ability to lower peripheral RIPK1 and IL-8 in ALS patients and delay disease progression in animal models highlights repurposing potential (source: Wei et al., 2023). These findings reinforce the value of RIPK1 and IL-8 as biomarkers and support further investigation into Primidone's utility in neurodegenerative and pain-related disorders. For deeper mechanistic and workflow insights, this article provides updated clinical and protocol guidance compared to previous ALS biomarker studies.